Structure-property relationships in ionically substituted bioactive glasses.

一种哲学：与其试图在体外重建活组织的复杂性，合成材料可以被配制成提供机械完整性，同时与细胞相互作用以释放身体固有的自我修复能力。瑞尔森大学的临床材料小组（CMG）在Towler的领导下，正在设计具有离子结合特性的玻璃基材料，以实现这一理念。该计划将建立在现有的出版（156篇同行评审论文）和专利（共6篇; 2篇在相关领域）研究的基础上，通过招募学生来实现四个目标：A.先进的知识。该计划将扩大对特定离子掺杂剂的作用的基本理解，以可量化的量，对离聚物玻璃和由它们制造的水泥材料的物理，机械和体外生物特性。该计划将有三个流：1。合成玻璃和玻璃聚烯烃酸盐水泥（GPC），使其具有足够的粘性以承受载荷。 2.溶胶-凝胶静电纺丝法将镓离子引入玻璃。 3.可再吸收GPC的开发。 B.培养下一代。将为学术、工业和监管行业培训高素质人员。他们的技能将通过与Towler在加拿大的学术，临床和工业合作者的实习来磨练。 C.确认研发投资的价值。通过该计划取得的进步将导致商业开发的知识产权。这项工作将吸引加拿大初创企业、中小型企业（SME）和跨国企业。Towler拥有许可（Opus-Fil+，DS&D，英国）和分拆（Crescent Ops，伦敦，英国）技术。 D.提高研究的可见度。Towler将继续在文献中广泛发表，至少保持他现有的速度（每年约15篇论文），并确保HQP在领先的科学会议上传播他们的工作。 在加拿大的前五年（2013-2018），Towler从NSERC和CIHR获得了超过260万加元的资金，使八名博士生和四名硕士生毕业，并指导四名PDF;该集团目前有11名研究生和三名PDF;所有这些都由联邦赠款资助，男女性别比例为50：50。新的HQP将从材料，生物和工程领域招募;职权范围是在加拿大战略利益领域对他们进行培训。 发现可交付成果可通过未来的NSERC I2 I或合作研发（CRD）或NSERC/CIHR合作健康研究项目（CHRP）赠款进行开发，并通过后续认证活动，可以改善骨科手术，从而缩短住院时间并降低医疗费用。

A philosophy: rather than attempting to recreate the complexity of living tissues ex vivo, synthetic materials can be formulated that offer mechanical integrity whilst interacting with cells to unlock the body's inherent ability to self-repair. The Clinical Materials Group (CMG) at Ryerson University, under the leadership of Towler, is designing glass-based materials with properties tailored by ionic incorporation in order to engage this philosophy. The program will build on existing published (156 peer-reviewed papers) and patented (six in total; two in the relevant space) research in Towler's laboratory by recruiting students to fulfil four objectives: A.Advance knowledge. The program will expand the fundamental understanding of the role that specific ionic dopants, in quantifiable amounts, have on the physical, mechanical and in-vitro biological properties of ionomeric glasses and cementitious materials manufactured from them. The program will have three streams: 1. Synthesis of glasses and glass polyalkenoate cements (GPCs) formulated to be sufficiently viscous for load bearing. 2. Incorporation of Gallium ions into glasses by sol-gel electro-spinning. 3. Development of a resorbable GPC. B.Inspire the next generation. Highly qualified personnel (HQP) will be trained for the academic, industrial and regulatory industries. Their skills will be honed by placements with Towler's academic, clinical and industrial collaborators across Canada. C.Confirm the value of R&D investment. Advancements made through the program will result in IP for commercial exploitation. The work will interest Canadian start-ups, small to medium enterprises (SME) and multinational industry. Towler has both licensed (Opus-Fil+, DS&D, UK) and spun-off (Crescent Ops, London, UK) technology. D.Increase visibility of research. Towler will continue to publish extensively in the literature, at the least maintaining his existing rate (~15 papers, annually) and ensuring HQP disseminate their work at leading scientific conferences. In his first five years in Canada (2013-2018), Towler secured over C$2.6m from NSERC and CIHR to graduate eight PhD and four MASc students and mentor four PDFs; the group currently has 11 graduate students and three PDFs; all funded by federal grants with a 50:50 gender balance between men and women. New HQP will be recruited from the materials, biology and engineering fields; the remit being to train them in areas of strategic interest to Canada.  Discovery deliverables may be exploited through future NSERC I2I or Collaborative Research & Development (CRD) or NSERC/CIHR Collaborative Health Research Project (CHRP) grants and, with follow-on accreditation activities, could improve orthopedic procedures leading to shorter hospital stays and reduced healthcare costs.